CFZ 533

Drug Profile

CFZ 533

Alternative Names: CFZ533; OM11-62-MF

Latest Information Update: 20 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD40 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Graves' disease; Myasthenia gravis; Sjogren's syndrome
  • Phase I/II Renal transplant rejection
  • Phase I Rheumatoid arthritis

Most Recent Events

  • 19 Dec 2017 Novartis completes a phase II trials in Myasthenia gravis (Adjunctive treatment) in Taiwan, Germany, Denmark, Canada and Russia (IV) (NCT02565576)
  • 29 Nov 2017 Novartis completes a phase-I/II clinical trials in Renal transplant rejection (Combination therapy) in Netherlands, Brazil, Spain, Germany and USA (IV) (NCT02217410)
  • 24 Apr 2017 Novartis completes a phase-II trial in Graves' disease in USA, Germany (NCT02713256)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top